Generic Medications Can Keep OOP Costs Down for Neurological Conditions
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Oct. 30, 2024 -- Generic medications reduce the out-of-pocket (OOP) costs for common neurological conditions, apart from multiple sclerosis, for which costs continue to increase, according to a study published online Oct. 30 in Neurology.
Amanda V. Gusovsky, Ph.D., M.P.H., from the Wexner Medical Center at The Ohio State University in Columbus, and colleagues examined medical cost trends for five common neurologic conditions. Annual OOP and total medication costs were quantified for 186,144 patients with epilepsy; 54,676 with multiple sclerosis; 45,909 with Parkinson disease; 169,127 with peripheral neuropathy; and 60,861 with dementia/Alzheimer disease who were seen by a neurologist.
The researchers observed an increase in OOP costs for multiple sclerosis medications, by an average of 217 percent. Higher OOP costs were seen for branded epilepsy medications versus generics. In the years after generic introduction, the annual OOP costs of duloxetine, pregabalin, rasagiline, rivastigmine, and memantine decreased 48 to 80 percent.
"Branded neurologic medication costs continue to increase. Using generics remains a powerful strategy for affordable prescribing," the authors write. "Multiple sclerosis medication costs remain exceptionally high, pose a substantial financial burden, and demand policy solutions such as cost caps."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2024
Read this next
Cognitive Therapy, Modafinil, Combo All Beneficial for Multiple Sclerosis Fatigue
FRIDAY, Oct. 25, 2024 -- Cognitive behavioral therapy (CBT), modafinil, and their combination are equally beneficial for multiple sclerosis fatigue, according to a study published...
Cancer Incidence Increased for People With Multiple Sclerosis
WEDNESDAY, Oct. 9, 2024 -- Cancer incidence is increased overall in people with multiple sclerosis (PwMS), with considerable differences depending on cancer type, age, and sex...
European Committee for Treatment and Research in Multiple Sclerosis, Sept. 18-20
The annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis was held from Sept. 18 to 20 in Copenhagen, Denmark, and drew more than 8,500...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.